The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Familial Amyloid Polyneuropathy-Global Market Insights and Sales Trends 2024
Synopsis
Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
The global Familial Amyloid Polyneuropathy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Familial Amyloid Polyneuropathy in various end use industries. The expanding demands from the Hospitals and Clinics and Others, are propelling Familial Amyloid Polyneuropathy market. FAP-I, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the FAP-II segment is estimated at % CAGR for the next seven-year period.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Familial Amyloid Polyneuropathy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Familial Amyloid Polyneuropathy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Familial Amyloid Polyneuropathy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Familial Amyloid Polyneuropathy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Familial Amyloid Polyneuropathy covered in this report include Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc.
The global Familial Amyloid Polyneuropathy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Global Familial Amyloid Polyneuropathy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Familial Amyloid Polyneuropathy market, Segment by Type:
FAP-I
FAP-II
FAP-III
FAP-IV
Global Familial Amyloid Polyneuropathy market, by Application
Hospitals and Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Familial Amyloid Polyneuropathy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
The global Familial Amyloid Polyneuropathy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Familial Amyloid Polyneuropathy in various end use industries. The expanding demands from the Hospitals and Clinics and Others, are propelling Familial Amyloid Polyneuropathy market. FAP-I, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the FAP-II segment is estimated at % CAGR for the next seven-year period.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Familial Amyloid Polyneuropathy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Familial Amyloid Polyneuropathy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Familial Amyloid Polyneuropathy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Familial Amyloid Polyneuropathy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Familial Amyloid Polyneuropathy covered in this report include Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience and Arcturus Therapeutics, etc.
The global Familial Amyloid Polyneuropathy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
Global Familial Amyloid Polyneuropathy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Familial Amyloid Polyneuropathy market, Segment by Type:
FAP-I
FAP-II
FAP-III
FAP-IV
Global Familial Amyloid Polyneuropathy market, by Application
Hospitals and Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Familial Amyloid Polyneuropathy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Familial Amyloid Polyneuropathy
1.1 Familial Amyloid Polyneuropathy Market Overview
1.1.1 Familial Amyloid Polyneuropathy Product Scope
1.1.2 Familial Amyloid Polyneuropathy Market Status and Outlook
1.2 Global Familial Amyloid Polyneuropathy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Familial Amyloid Polyneuropathy Market Size by Region (2018-2029)
1.4 Global Familial Amyloid Polyneuropathy Historic Market Size by Region (2018-2023)
1.5 Global Familial Amyloid Polyneuropathy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Familial Amyloid Polyneuropathy Market Size (2018-2029)
1.6.1 North America Familial Amyloid Polyneuropathy Market Size (2018-2029)
1.6.2 Europe Familial Amyloid Polyneuropathy Market Size (2018-2029)
1.6.3 Asia-Pacific Familial Amyloid Polyneuropathy Market Size (2018-2029)
1.6.4 Latin America Familial Amyloid Polyneuropathy Market Size (2018-2029)
1.6.5 Middle East & Africa Familial Amyloid Polyneuropathy Market Size (2018-2029)
2 Familial Amyloid Polyneuropathy Market by Type
2.1 Introduction
2.1.1 FAP-I
2.1.2 FAP-II
2.1.3 FAP-III
2.1.4 FAP-IV
2.2 Global Familial Amyloid Polyneuropathy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Type (2018-2023)
2.2.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Familial Amyloid Polyneuropathy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Familial Amyloid Polyneuropathy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Familial Amyloid Polyneuropathy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Familial Amyloid Polyneuropathy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Familial Amyloid Polyneuropathy Revenue Breakdown by Type (2018-2029)
3 Familial Amyloid Polyneuropathy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Others
3.2 Global Familial Amyloid Polyneuropathy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Application (2018-2023)
3.2.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Familial Amyloid Polyneuropathy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Familial Amyloid Polyneuropathy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Familial Amyloid Polyneuropathy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Familial Amyloid Polyneuropathy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Familial Amyloid Polyneuropathy Revenue Breakdown by Application (2018-2029)
4 Familial Amyloid Polyneuropathy Competition Analysis by Players
4.1 Global Familial Amyloid Polyneuropathy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2022)
4.3 Date of Key Players Enter into Familial Amyloid Polyneuropathy Market
4.4 Global Top Players Familial Amyloid Polyneuropathy Headquarters and Area Served
4.5 Key Players Familial Amyloid Polyneuropathy Product Solution and Service
4.6 Competitive Status
4.6.1 Familial Amyloid Polyneuropathy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Familial Amyloid Polyneuropathy Products, Services and Solutions
5.1.4 Pfizer Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 GSK
5.2.1 GSK Profile
5.2.2 GSK Main Business
5.2.3 GSK Familial Amyloid Polyneuropathy Products, Services and Solutions
5.2.4 GSK Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.2.5 GSK Recent Developments
5.3 Ionis
5.3.1 Ionis Profile
5.3.2 Ionis Main Business
5.3.3 Ionis Familial Amyloid Polyneuropathy Products, Services and Solutions
5.3.4 Ionis Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.3.5 Alnylam Recent Developments
5.4 Alnylam
5.4.1 Alnylam Profile
5.4.2 Alnylam Main Business
5.4.3 Alnylam Familial Amyloid Polyneuropathy Products, Services and Solutions
5.4.4 Alnylam Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.4.5 Alnylam Recent Developments
5.5 Corino Therapeutics
5.5.1 Corino Therapeutics Profile
5.5.2 Corino Therapeutics Main Business
5.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Products, Services and Solutions
5.5.4 Corino Therapeutics Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.5.5 Corino Therapeutics Recent Developments
5.6 Proclara Bioscience
5.6.1 Proclara Bioscience Profile
5.6.2 Proclara Bioscience Main Business
5.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Products, Services and Solutions
5.6.4 Proclara Bioscience Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.6.5 Proclara Bioscience Recent Developments
5.7 Arcturus Therapeutics
5.7.1 Arcturus Therapeutics Profile
5.7.2 Arcturus Therapeutics Main Business
5.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Products, Services and Solutions
5.7.4 Arcturus Therapeutics Familial Amyloid Polyneuropathy Revenue (US$ Million) & (2018-2023)
5.7.5 Arcturus Therapeutics Recent Developments
6 North America
6.1 North America Familial Amyloid Polyneuropathy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Familial Amyloid Polyneuropathy Market Dynamics
11.1 Familial Amyloid Polyneuropathy Industry Trends
11.2 Familial Amyloid Polyneuropathy Market Drivers
11.3 Familial Amyloid Polyneuropathy Market Challenges
11.4 Familial Amyloid Polyneuropathy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
